Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 showed $27M GAAP net income, $749M revenue, and $40M adjusted EBITDA, with membership up 51% YoY. Positive Medicare Advantage sentiment from the CMS 2027 rate increase and a roughly 46% 21-day rally support near-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Fading rebounds ⢠Support holding ⢠Mid-$4 resistance Support Level: $4.30-$4.40 Resistance Level: $4.55-$4.80 CLOV has weakened over the last month, with repeated buying near $4.30â$4.40 forming support, but fading rebounds and overhead resistance in the mid-$4s keep the near-term bias fragile unless $4.30 holds.
Sentiment & News
Key News Insights: ⢠Earnings visibility ⢠Insider selling ⢠Cyber incident Clover Health is spotlighting upcoming earnings and conference visibility, but insider selling and a reported account breach are the main near-term overhangs. ŕ´
AI Summary
CLOV has shifted from a speculative âstory stockâ to a real operating inflection as membership, revenue, and EBITDA scale toward potential GAAP profitability in 2026, but the investment now hinges on whether it can sustain margins, star ratings, and execution without cost or compliance slippage.
Description
Clover Health Investments, Corp. is a U.S. insurer that offers Medicare Advantage products to eligible beneficiaries, delivering plan administration through its Clover Assistant software platform and operating both PPO and HMO plan types. The company also conducts non-insurance activities alongside its core insurance business. Founded in 2014, Clover Health is headquartered in Franklin, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 7 | May 14 | CLOV | Clover Health Investments, Corp. | Q1 2026 showed $27M GAAP net income, $749M revenue, and $40M adjusted EBITDA, with membership up 51% YoY. Positive Medicare Advantage sentiment from the CMS 2027 rate increase and a roughly 46% 21-day rally support near-term upside. | Closed | +23.8% |